Dr. Vijay Patel
Claim this profileFlorida Cancer Specialists
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
36 drugs studied
About Vijay Patel
Education:
- Graduated from Ross University School of Medicine, Dominica.
- Completed Residency in Internal Medicine/Pediatrics at the University of Kansas Medical Center, Kansas City, KS.
- Undertook Fellowship in Hematology/Oncology at the University of Kansas Medical Center, Kansas City, KS.
Experience:
- Began his career as a community oncologist/hematologist in 2008 at the University of Kansas Medical Center.
- Served as Director of Cancer and Palliative Care departments at West Jefferson Medical Center, Marrero, LA (2011-2015).
- Board Certified in Medical Oncology, Hematology, and Internal Medicine.
- Affiliated with Florida Cancer Specialists & Research Institute, Gainesville and Lake City locations.
- Published extensively and presented at national conferences in his field.
Area of expertise
1Lung Cancer
PD-L1 positive
Stage IV
Stage III
2Non-Small Cell Lung Cancer
PD-L1 positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Vijay Patel is currently running
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting1 award Phase 1 & 29 criteria
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting1 award Phase 211 criteria
More about Vijay Patel
Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Vijay Patel has experience with
- Placebo
- Carboplatin
- Etrumadenant
- Pembrolizumab
- Pemetrexed
- Fruquintinib
Breakdown of trials Vijay Patel has run
Lung Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Vijay Patel specialize in?
Vijay Patel focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved PD-L1 positive patients, or patients who are Stage IV.
Is Vijay Patel currently recruiting for clinical trials?
Yes, Vijay Patel is currently recruiting for 2 clinical trials in Saint Petersburg Florida. If you're interested in participating, you should apply.
Are there any treatments that Vijay Patel has studied deeply?
Yes, Vijay Patel has studied treatments such as Placebo, Carboplatin, Etrumadenant.
What is the best way to schedule an appointment with Vijay Patel?
Apply for one of the trials that Vijay Patel is conducting.
What is the office address of Vijay Patel?
The office of Vijay Patel is located at: Florida Cancer Specialists, Saint Petersburg, Florida 33705 United States. This is the address for their practice at the Florida Cancer Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.